Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.05 USD
631.46 M USD
2.39 B USD
635.23 M
About GENMAB A/S
Sector
CEO
Jan G. J. van de Winkel
Headquarters
Copenhagen
Website
Founded
1998
FIGI
BBG004MPKM64
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where GMAB is featured.